Published in final edited form as:

Fertil Steril. 2014 April ; 101(4): 1142–1148. doi:10.1016/j.fertnstert.2013.12.046.

Gonadal dysfunction in Morbidly Obese Adolescent Girls

Vivian Chin, MD¹, Marisa Censani, MD¹, Shula Lerner, MD¹, Rushika Conroy, MD¹, Sharon Oberfield, MD¹, Donald McMahon, MS², Jeffrey Zitsman, MD³, and Ilene Fennoy, MD, MPH¹

¹Dept of Pediatrics, Division of Pediatric Endocrinology, Columbia University Medical Center, New York, NY, United States, 10032

²Dept of Medicine, Columbia University Medical Center, New York, NY, United States, 10032

³Dept of Surgery, Columbia University Medical Center, New York, NY, United States, 10032

Abstract

Objective—To describe gonadal dysfunction and evaluate polycystic ovary syndrome (PCOS) and its association with metabolic syndrome (MeS) among girls in a morbidly obese adolescent population.

Design—In a cross-sectional study of 174 girls, height, weight, waist circumference, Tanner stage, reproductive hormones, carbohydrate and lipid markers, drug use and menstrual history were obtained at baseline. Exclusion criteria: menarchal age < 2 years, hormonal contraceptive or Metformin use, Tanner stage <4, incomplete data on PCOS or MeS classification.

Setting—University Medical Center outpatient clinic

Patients—98 girls ages 13–19.6 years, Tanner 5, average BMI of 46.6 kg/m², menarche at 11.4 years and average menarchal age of 5 years

Interventions—None

Main Outcome Measures—PCOS and MeS

Results—98 girls were divided into 4 groups: PCOS by NIH criteria (PCOS_N, n=24), irregular menses only (IM, n=25), elevated testosterone > 55 ng/dL only (ET, n=6) and obese controls (OC, n=43). MeS by modified Cook criteria affected 32 girls or 33% overall, 6/24 PCOS_N, 7/25 IM, 4/6 ET and 15/43 OC. PCOS_N and its individual components were not associated with MeS after adjusting for BMI.

Conclusion—Unlike obese adults, PCOS_N and its individual components were not associated with MeS in the untreated morbidly obese adolescent population.

Keywords

Metabolic Syndrome; polycystic ovary syndrome; bariatric surgery; morbid obesity

© 2013 Published by Elsevier Inc on behalf of American Society for Reproductive Medicine.

Address correspondence and reprint requests to: Ilene Fennoy, MD, MPH, Columbia University Medical Center, 622 West 168th Street, PH 5E-522, New York, New York 10032, Telephone: (212) 305-6559, Fax: (212) 305-4778, if1@cumc.columbia.edu.

The authors have no known or perceived conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Introduction

PCOS is a condition of anovulation, clinical or biochemical hyperandrogenism, and/or polycystic ovaries and is the most common endocrinopathy of reproductive-aged women, affecting 5–7% by the strictest criteria. Obesity increases this risk with 25% of overweight and obese women, rising to as high as 35% of morbidly obese women affected with PCOS (1–3). Metabolic syndrome (MeS) refers to a constellation of risk factors such as insulin resistance, hyperglycemia, hypertension, low high-density lipoprotein (HDL) cholesterol, and increased low density lipoproteins (LDL)(4). MeS and its components increase an individual's overall risk for type 2 diabetes, cardiovascular disease (CVD) and mortality due to CVD(5, 6). Women with PCOS often have CVD, and it is unclear whether this risk is due to the increased prevalence of MeS. MeS affects 43–50% of women with PCOS compared to about 25% of the general population(7–10). Studies have shown that MeS prevalence in adult women with PCOS is two to three times higher than control women after adjusting for BMI(9, 11, 12).

Morbidly obese adolescents often have multiple comorbidities including hypertension, obstructive sleep apnea, hyperlipidemia, type 2 diabetes, metabolic syndrome, hepatic steatosis and depression. However, gonadal dysfunction in the morbidly obese group has not been well studied. A literature search revealed few reports with mention of amenorrhea, irregular menses, hirsutism and PCOS among adolescent girls in bariatric surgery programs(13–16). The childhood obesity rate is alarmingly high and identification of PCOS and MeS as cardiovascular risk factors in childhood should be considered as 77% of overweight children remain overweight as adults(17). Childhood MeS status has been shown to predict the risk for MeS in adulthood as well as type 2 diabetes in 25–30 years(18). MeS affects 8.6% of children, but is much higher, nearly 30% in overweight adolescents(19, 20). While the relationship between PCOS and MeS has been well studied and verified in adults, it is not as well defined in adolescents. Some reports show that MeS affects between 10.8% to 37% of adolescent girls with PCOS while others report that PCOS does not confer additional risk for MeS (21–23). Like adult women, adolescents with PCOS are insulin resistant and PCOS may be able to predict MeS based on this mechanism(24, 25). The objective of this study is to describe gonadal dysfunction and to determine whether PCOS can predict MeS in a group of adolescent girls with morbid obesity being evaluated for bariatric surgery.

Subjects and Methods

The study was approved by the Institutional Review Board at Columbia University Medical Center. Written informed consent was obtained from all participants and their parents or legal guardians prior to enrollment. All authors have no known or perceived conflicts of interest. All adolescent girls who were being evaluated for bariatric surgery in the Center for Adolescent Bariatric Surgery program at Columbia University Medical Center had baseline measures taken. Height, weight, waist circumference (WC), blood pressure (BP), Tanner stage, reproductive hormones, carbohydrate and lipid markers, drug use and menstrual history were obtained. Height, weight, WC and BP were measured as previously reported(26). Laboratory values were performed after an overnight fast between the hours 8:00 am and 10:00 am with hormonal assays performed at Esoterix, Inc, a specialized endocrine laboratory that measures insulin by immunochemiluminometric assay, total and free testosterone and sex hormone binding globulin (SHBG) by HPLC tandem mass spectrometry by equilibrium dialysis, and luteinizing hormone (LH) and follicle stimulating hormone (FSH) by electrochemiluminometric assay. Glucose, lipids, liver function tests, and chemistries were performed at the laboratory of New York Presbyterian Hospital. The homeostatic index of insulin resistance or HOMA-IR was calculated using the following

formula: $\text{HOMA-IR} = [\text{fasting insulin } (\mu\text{U/mL}) \times \text{fasting glucose (mmol/liter)}] / 22.5$ (27). Two hour oral glucose tolerance test was performed using the standard 75 grams of glucose. Area under the curve for glucose (AUC-G₁₂₀) and insulin (AUC-I₁₂₀) was calculated using the trapezoidal rule and 4 data points at 0, 30, 60 and 120 minutes (28). Height percentile, weight percentile, BMI percentile and BMI z-score adjusted for age and sex were calculated using EpiInfo, version 3.5.3, provided by the Centers for Disease Control. BP percentile adjusted for height and sex was calculated based on The Fourth Report using an online calculator from Uptodate.com (29).

Diagnosis of PCOS and MeS

Diagnosis of PCOS defined by NIH criteria was made if both criteria were met: 1) clinical or biochemical hyperandrogenism (total testosterone (T) ≥ 55 ng/dl) and 2) oligomenorrhea with <8 cycles per year or amenorrhea (30). Clinical hyperandrogenism which included signs like acne or hirsutism were not systematically recorded, but when present was used in the diagnosis of PCOS_N. Girls with previous history of PCOS without confirmation of NIH criteria were not classified in the PCOS_N group. Other endocrinopathies were excluded. Diagnosis of MeS defined by the modified Cook criteria is fulfilled if 3 out of the following 5 were met: 1) fasting blood glucose (FBG) ≥ 100 mg/dl, modified to the 2003 ADA criterion, 2) triglycerides (TG) ≥ 110 mg/dl, 3) high density lipoprotein (HDL) ≤ 40 mg/dl, 4) WC $\geq 90^{\text{th}}$ percentile for ethnicity, age and sex, and 5) systolic or diastolic BP $\geq 90^{\text{th}}$ percentile for age, height and sex (20).

Only girls with complete data on menstrual history, total testosterone values, FBG, TG, HDL, WC and BP were included in the study. All girls were at least 2 years post menarche. Girls who did not have complete data, were <2 years post menarchal age, $<$ Tanner 4 staging or treated with hormonal contraceptives like oral contraceptive pills (OCPs) or intrauterine device (IUD) or insulin sensitizing agents like Metformin for any reason were excluded.

Statistics

Group comparisons of multiple means were performed using ANOVA and adjustment for multiple means comparisons was performed using Scheffe's test. Fisher's exact test was performed for tests of proportions. SAS software was used. An alpha level of 0.05 or less was considered statistically significant. Logistic regression modeling was used to examine predictors of metabolic syndrome using PCOS and its individual components as independent variables after adjusting for BMI.

Results

174 girls were enrolled in the Center for Adolescent Bariatric Surgery program at Columbia University Medical Center from 2006 to 2013. After exclusion of 29 girls with missing data, 7 girls with menarchal age <2 years, 1 girl with Tanner 3 staging, 16 girls on Metformin, 16 girls on hormonal contraceptive and 7 girls on both, data from 98 girls were analyzed. They were divided into 4 groups: PCOS by NIH criteria (PCOS_N, n=24), irregular menses only (IM, n=25), elevated testosterone only (ET, n=6) and obese controls (OC, n=43).

98 girls, ages 13 to 19.6 years, mean age 16.4 years (SD 1.3), Tanner 5, with an average BMI of 46.6 kg/m^2 (SD 7.3) and average menarchal age of 5 years (SD 1.7) were included in the study. They were predominantly Caucasian (42/98) and Hispanic (32/98) while the rest were identified as African American (19/98), Asian (1/98) and other/unknown (4/98). 24.5% (24/98) were diagnosed with PCOS by NIH criteria, 25.5% (25/98) had irregular menses only, 6% (6/98) had elevated testosterone only and 44% (43/98) were obese controls. All 4 groups were similar in their chronological age, weight and age of menarche

(Table 1). BMI was significantly higher in the IM group compared to OC group (49.8 vs 44.4 kg/m², $p=0.03$). Menarchal age was greater in PCOS_N than in OC (5.9 vs 4.7 years, $p=0.03$). For MeS components, all 4 groups were similar in their HDL, triglycerides, systolic and diastolic BP, WC and fasting glucose. Measures of insulin resistance (HOMA-IR, HgbA1c, AUC-I₁₂₀, fasting insulin), metabolic parameters (total cholesterol and LDL, AST, ALT) as well as hormonal values (LH, FSH, estradiol, SHBG) were similar in all 4 groups. PCOS_N had the highest AUC-G₁₂₀ of 130.4 mg/dL/minute compared to OC with a level of 109.4 mg/dL/minute ($p=0.018$). As expected, total testosterone levels were significantly different between groups with ET having the highest mean testosterone of 67 ng/dL, followed by PCOS_N with mean testosterone of 60.9 ng/dL, compared to IM and OC groups with lower testosterone levels of 32.2 and 31.9 ng/dL, respectively ($p<0.0001$). Free testosterone was also elevated in PCOS_N compared to IM and OC (11.5, 5.4, 5.2 pg/mL respectively, $p<0.0001$). MeS by modified Cook criteria affected 32 girls or 33% overall while affecting 25% of PCOS_N, 28% of IM, 67% of ET and 35% of OC, which is statistically similar among all groups (Figure 1, $p=0.27$).

PCOS and individual components of PCOS do not predict MeS

To answer the question whether PCOS status can predict MeS status, three models were created by logistic regression analysis (Table 2). To model MeS, the dependent variable, we used PCOS components (irregular menses and testosterone separately) as independent predictors while controlling for BMI in model #1 and model #2, respectively. In model #3, PCOS status itself was used as an independent predictor of MeS while controlling for BMI. Neither irregular menses in model #1 (OR=0.4, CI 0.16–1.04) nor testosterone levels in model #2 (OR=1.07, CI 0.38–2.99) were significant predictors of MeS after adjusting for BMI. In model #3, PCOS status (OR=0.59, CI 0.19–1.63) itself was not a significant predictor of MeS after adjusting for BMI.

Discussion

The identification of adolescents with PCOS is often difficult due to the transient and physiologic nature of features such as irregular menses and polycystic ovary morphology in addition to difficulty in interpretation of clinical and biochemical evidence of hyperandrogenism. Three diagnostic criteria for PCOS exist: 1990 NIH criteria, Androgen Excess Society (AES) criteria and the Rotterdam criteria. The NIH criteria requires anovulation/oligomenorrhea and clinical or biochemical hyperandrogenism while the appearance of polycystic ovaries is not required for the diagnosis of PCOS. The Androgen Excess criteria require hyperandrogenism/hyperandrogenemia and one additional criterion, while the Rotterdam criteria does not specify which two of the three must be met.

While menstrual irregularity in adults indicates anovulation of clinical significance, a feature in all three diagnostic criteria for PCOS, this is less dependable in adolescents. During the first 2 years after menarche, anovulatory cycles are common, affecting about 50% of the cycles while the hypothalamic-pituitary-ovarian (HPO) axis matures(31). Maturation of the HPO axis occurs as FSH secretion rises and pulsatility of LH is established and frequency increases to adult patterns by Tanner stages 4–5(32). About 95% of the ovulatory cycles reach 21–45 day range with periods lasting 2–7 days in the third year post-menarche(33). van Hooff et al. found more than half of the girls studied in his population cohort with oligomenorrhea at age 15 remained so at age 18 and elevated LH, DHEAS and testosterone levels were strong predictors for persistent oligomenorrhea(34). This suggests that oligomenorrhea and anovulatory cycles that persist past 2 years post-menarche are associated with PCOS. Roe et al. studied a group of adolescents with PCOS based on AES criteria and found that 98% of the girls reported menstrual irregularity, followed by acne, hirsutism and weight gain(22). One must also take into account the age of menarche, the

earlier the onset of menarche, the shorter the expected duration of oligomenorrhea due to anovulatory cycles(35). In our study, the average menarchal age was 5 years. Acne, a common complaint among adolescents, may resolve or improve over time. Hickey et al reports that 70% of adolescents girls had signs of mild to severe acne which were not associated with elevated levels of free testosterone(36). Establishment of clinical hyperandrogenism in adolescent girls with hirsutism is problematic as the Ferriman-Gallway scoring system is standardized primarily on white women, mostly over 24 years of age(37). Variable degrees of hirsutism among different ethnicities and differing sensitivity to androgens also make establishment of clinical hyperandrogenism difficult (38). According to Lucky et al, upper lip hair is a very common complaint among black adolescent girls 2 years post-menarche, affecting 49% versus 9% of white subjects and was not associated with elevated levels of testosterone(38). It has been suggested that progressive hirsutism is the best clinical marker for PCOS(39). Establishment of biochemical hyperandrogenism is also fraught with difficulty due to variable sensitivities of hormonal assays, limitations due to lack of normative data and diurnal variations in detection of testosterone (11). In 2007, the Endocrine Society released a position statement that recommended total testosterone detection should be completed with sensitive assays such as chromatography/mass spectrometry rather than direct immunoassays, in conjunction with well-established references values(11, 40). Carmina et al have suggested using a threshold total testosterone value as high as >2 SD above the mean or >55–59 ng/dL during the hours of 0800–1000 during the follicular phase to define hyperandrogenism for PCOS(41). Use of free testosterone is generally not recommended in girls due to lack of sufficient normative data.

Sonographic evidence of polycystic ovarian morphology is difficult to interpret in adolescents and can be found in as many as 40% healthy girls without pathology 2 years post-menarche(42). Physiologically, ovarian volume is low during the pre-pubertal period and reaches maximum volume and antral follicle count during menarche followed by a progressive decline in size and follicle number until menopause(43). These natural changes over time makes the appearance of polycystic ovaries difficult to interpret as many normal healthy girls have been found to satisfy the criteria of ovarian volume >10 mL or greater than twelve 2–9 mm follicles for polycystic ovary morphology (42, 44). Adding to the difficulty is the limited use of transvaginal ultrasonography in virginal patients and the difficulty in obtaining high quality transabdominal images in overweight and obese adolescent girls(45). In an Australian-based population study, polycystic ovarian morphology was of limited use in the diagnosis of PCOS in adolescents since only 35% met the criteria for abnormal ovarian morphology or size(36). There are suggestions by various groups to redefine the threshold mean ovarian volume (MOV) based on different imaging modalities. MOVs of 5.6 ml for transabdominal and 6.74 ml for transvaginal ultrasounds were suggested as new threshold values with good accuracy for polycystic ovary morphology(46, 47). Given all these limitations and the large body habitus of our subjects with an average WC of 132 cm, transabdominal pelvic ultrasounds were not routinely performed in our subjects. Additionally, polycystic ovarian morphology is not a required to satisfy NIH criteria.

To the best of our knowledge, this study is the first to examine gonadal dysfunction in morbidly obese adolescent girls. Twenty-five percent of our untreated morbidly obese adolescents were affected by PCOS_N which is slightly lower than what is expected in the adult population, while 28% had irregular menses only without any evidence of clinical or biochemical hyperandrogenism and 6% had elevated testosterone greater than 55 ng/dL only and no evidence of menstrual irregularity.

Adolescents with PCOS have higher rates of insulin resistance than normal controls. Impaired glucose tolerance (IGT), an indicator of insulin resistance, affects been between 10

and 30% of adolescents with PCOS based on several studies (23, 24, 48). The gold standard used to assess reduced sensitivity to insulin is the euglycemic hyperinsulinemic clamp, but high costs and impracticality limits its use in clinical practice(49). Therefore, an oral glucose tolerance test is frequently used. A 75-gram glucose load performed on all our subjects revealed that the AUC-G₁₂₀ was significantly higher for the PCOS_N group than the OC group despite no differences in AUC-I₁₂₀, HgbA1c or HOMA-IR. Both groups had statistically similar BMI values. Perhaps this difference in glucose reflects deteriorating insulin sensitivity given that girls in the PCOS_N group may have had the disease process for a few years. These results are consistent with the increased risk for insulin resistance in girls with PCOS.

We found no association between PCOS and MeS in the bariatric population among those without treatment and no clustering of PCOS components with MeS, which is contrary to adult data and a few previously published pediatric reports. Coviello et al using the NHANES III cohort, described girls with PCOS diagnosed by NIH criteria as being 4.5 times more likely than control girls to have MeS even after adjusting for BMI, however the presence of PCOS was not verified in the control group(21). Similarly, Roe et al identified 10% of girls with PCOS by Androgen Excess Criteria who had MeS compared to 1.7% in girls without PCOS. However, the study was limited by the use of BMI as a surrogate for waist circumference in the diagnosis of MeS and the use of controls who had some features of PCOS but not the full phenotype(22). In a study of girls with PCOS and their parental MeS status, it was found that MeS was 3 fold higher than expected for obesity status in girls with PCOS(12). On the other hand, among overweight and obese adolescents, PCOS status did not confer increased risk of MeS regardless of the definition of MeS used(23). These differing conclusions may be explained by lack of consensus in defining MeS among adults and adolescents(50). For adults, MeS criteria have been defined by various groups such as the World Health Organization, NCEP Adult Treatment Panel (ATP) III, and the European Group for the Study of Insulin Resistance. In pediatrics, the modified Cook criteria, de Ferranti criteria and International Diabetes Federation criteria have been used (20, 51–53). In adults, the ATP III definition is frequently used, incorporating features such as insulin resistance, central obesity, dyslipidemia, and hypertension without requiring any one be a key feature(54). In 2003, Cook modified the adult ATP III criteria for children; these criteria are widely used in the study of MeS in children, including this study. It remains difficult to conclusively determine whether there is an association between PCOS and MeS given differing criteria used to define MeS among adults and adolescents.

Adding to the inconsistencies is the heterogeneity of PCOS. All three diagnostic criteria were used in various studies to describe the association between PCOS and MeS. According to Welt et al and Robinson et al those who met the NIH criteria were the most metabolically abnormal while those who met Rotterdam criteria, with PCO morphology and ET or PCO morphology and IM were less insulin resistant and had lower BMI. PCOS based on differing diagnostic criteria is a heterogenous syndrome with varying metabolic dysfunction (55, 56).

Ethnic differences in PCOS phenotype have been studied and may explain the variable association between MeS and PCOS among the pediatric population(57). A majority of studies finding a positive association between PCOS and MeS had participants from the US who were mainly of Caucasian background (9, 11, 58). In northern California, Hispanic women with PCOS were more likely to be obese and have type 2 diabetes than Caucasian and Black women respectively (59). Our study's participants varied in ethnicity, the majority being Caucasian and Hispanic background. We expected our morbidly obese group to be more metabolically abnormal than previously studied groups consisting of mainly Caucasian women with lower average BMI. However, the prevalence of MeS was comparable to the prevalence among adult women studied. In a study of 394 women with

PCOS by Ehrmann et al, MeS was found to be 13.7 times more likely in the top BMI quartile compared to those in the lowest quartile(58). In our study, BMI of all subjects was greater than 99th percentile, but only 33% of the group overall had MeS and only 25% of PCOS_N were affected. PCOS and MeS prevalence may not be accurate due to exclusion of girls already treated with OCPs and/or Metformin. Some girls who came in with a diagnosis of PCOS remained excluded from data analysis due to inability to confirm the diagnosis while on treatment. However, OCPs were also started for reasons other than for PCOS such as for contraception or for regulation of menses including problems such as dysfunctional uterine bleeding. Girls who were treated with metformin without a confirmed documentation of impaired fasting glucose or impaired glucose tolerance while on treatment also remained excluded. The effect of exclusion of these girls on our data analysis is unknown and we cannot presume that these girls were more metabolically unhealthy or severely affected, other than the fact that they were on metformin and/or OCPs for unknown reasons.

The mechanism behind the association between PCOS and MeS frequently has been cited to be insulin resistance and abdominal obesity. In women with PCOS, hyperinsulinism acts synergistically with LH within the theca cells of the ovary to cause increased synthesis of testosterone (60). Between 50%–60% of women with PCOS are affected by an increase of abdominal subcutaneous and visceral fat depots known as android body fat distribution (BFD) regardless of BMI(61). There is evidence to suggest that insulin resistance may be a consequence of android BFD, as well as possibility that android BFD can both be a cause and effect of hyperandrogenemia(61). This suggests that central adiposity and insulin resistance play prominent roles in PCOS.

In girls with PCOS, age of menarche has been reported to be earlier or later than controls due to various factors. Some girls with PCOS who report histories of premature pubarche may have early menarche but other girls who present with primary amenorrhea are later diagnosed with PCOS(62, 63). According to Carroll et al, among girls with PCOS_N, BMI and age of menarche are negatively correlated but were not different from controls with average age of menarche of 12.72 vs 12.5 years(64). In the same study, chromosome 6 rs7759938-T variant was found to be associated with earlier age at menarche in women with PCOS. In our study, average age of menarche trended in the PCOS_N group as the earliest at 10.7 years ($p=0.056$). Not surprisingly, the menarchal age was the highest in the PCOS_N group at 5.9 years compared to 4.8, 4.7 and 4.7 years in the IM, ET and OC groups, respectively. Given the younger age of menarche and the highest post-menarchal age in the PCOS_N group, the presence of oligomenorrhea is likely more indicative of anovulation than of an immature HPO axis.

Conclusion

In the adolescent bariatric population untreated with oral contraceptive pills and/or metformin, prevalence of PCOS_N was 24.5% while 25% of this group had MeS. Overall 33% of the untreated morbidly obese adolescent girls had MeS. Metabolic syndrome and its individual components were not associated with PCOS status in the morbidly obese adolescent population, contrary to adult data. While descriptions of gonadal function are rare in this group, this study is the largest adolescent bariatric group assessed to date. Further investigation is warranted to clarify the relationship between obesity and gonadal dysfunction in the morbidly obese adolescent.

Acknowledgments

This work was supported by NIH Grants NIDDK T32 DK 06552 for Sharon Oberfield, Department of Pediatrics, Division of Pediatric Endocrinology, New York, NY 10032.

References

1. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod Update*. 2012; 18(6):618–37. [PubMed: 22767467]
2. Alvarez-Blasco F, Botella-Carretero JJ, San Millan JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. *Arch Intern Med*. 2006; 166(19):2081–6. [PubMed: 17060537]
3. Escobar-Morreale HF, Botella-Carretero JJ, Alvarez-Blasco F, Sancho J, San Millan JL. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. *J Clin Endocrinol Metab*. 2005; 90(12):6364–9. [PubMed: 16189250]
4. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes*. 1988; 37(12):1595–607. [PubMed: 3056758]
5. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. *J Clin Endocrinol Metab*. 2010; 95(5):2038–49. [PubMed: 20375205]
6. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care*. 2001; 24(4):683–9. [PubMed: 11315831]
7. Carmina E. Metabolic syndrome in polycystic ovary syndrome. *Minerva Ginecol*. 2006; 58(2):109–14. [PubMed: 16582867]
8. Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. *J Endocrinol Invest*. 2006; 29(3):270–80. [PubMed: 16682845]
9. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. *J Clin Endocrinol Metab*. 2005; 90(4):1929–35. [PubMed: 15623819]
10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA*. 2002; 287(3):356–9. [PubMed: 11790215]
11. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. *Metabolism*. 2003; 52(7):908–15. [PubMed: 12870169]
12. Leibel NI, Baumann EE, Kocherginsky M, Rosenfield RL. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome. *J Clin Endocrinol Metab*. 2006; 91(4):1275–83. [PubMed: 16449341]
13. Nadler EP, Youn HA, Ren CJ, Fielding GA. An update on 73 US obese pediatric patients treated with laparoscopic adjustable gastric banding: comorbidity resolution and compliance data. *J Pediatr Surg*. 2008; 43(1):141–6. [PubMed: 18206472]
14. Abu-Abeid S, Gavert N, Klausner JM, Szold A. Bariatric surgery in adolescence. *J Pediatr Surg*. 2003; 38(9):1379–82. [PubMed: 14523824]
15. Collins J, Mattar S, Qureshi F, Warman J, Ramanathan R, Schauer P, et al. Initial outcomes of laparoscopic Roux-en-Y gastric bypass in morbidly obese adolescents. *Surg Obes Relat Dis*. 2007; 3(2):147–52. [PubMed: 17324636]
16. Sugerman HJ, Sugerman EL, DeMaria EJ, Kellum JM, Kennedy C, Mowery Y, et al. Bariatric surgery for severely obese adolescents. *J Gastrointest Surg*. 2003; 7(1):102–7. discussion 7–8. [PubMed: 12559191]
17. Freedman DS, Khan LK, Dietz WH, Srinivasan SR, Berenson GS. Relationship of childhood obesity to coronary heart disease risk factors in adulthood: the Bogalusa Heart Study. *Pediatrics*. 2001; 108(3):712–8. [PubMed: 11533341]
18. Morrison JA, Friedman LA, Wang P, Glueck CJ. Metabolic syndrome in childhood predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years later. *J Pediatr*. 2008; 152(2):201–6. [PubMed: 18206689]

19. Johnson WD, Kroon JJ, Greenway FL, Bouchard C, Ryan D, Katzmarzyk PT. Prevalence of risk factors for metabolic syndrome in adolescents: National Health and Nutrition Examination Survey (NHANES), 2001–2006. *Arch Pediatr Adolesc Med.* 2009; 163(4):371–7. [PubMed: 19349567]
20. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. *Arch Pediatr Adolesc Med.* 2003; 157(8):821–7. [PubMed: 12912790]
21. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. *J Clin Endocrinol Metab.* 2006; 91(2):492–7. [PubMed: 16249280]
22. Roe AH, Prochaska E, Smith M, Sammel M, Dokras A. Using the androgen excess-PCOS society criteria to diagnose polycystic ovary syndrome and the risk of metabolic syndrome in adolescents. *J Pediatr.* 2013; 162(5):937–41. [PubMed: 23260096]
23. Rossi B, Sukalich S, Droz J, Griffin A, Cook S, Blumkin A, et al. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2008; 93(12):4780–6. [PubMed: 18812482]
24. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2002; 87(3):1017–23. [PubMed: 11889155]
25. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. *J Clin Endocrinol Metab.* 2001; 86(1):66–71. [PubMed: 11231980]
26. Conroy R, Lee EJ, Jean A, Oberfield SE, Sopher A, Kiefer K, et al. Effect of laparoscopic adjustable gastric banding on metabolic syndrome and its risk factors in morbidly obese adolescents. *J Obes.* 2011; 2011:906384. [PubMed: 21188168]
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia.* 1985; 28(7):412–9. [PubMed: 3899825]
28. Yeh KC, Kwan KC. A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. *J Pharmacokinet Biopharm.* 1978; 6(1):79–98. [PubMed: 650423]
29. National High Blood Pressure Education Program Working Group on High Blood Pressure in C, Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics.* 2004; 114(2 Suppl 4th Report):555–76. [PubMed: 15286277]
30. Dunaif, AGJ.; Haseltine, FP.; Merrim, GR., editors. *Polycystic Ovary Syndrome.* Blackwell Scientific Publications; Boston: 1992. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach; p. 377–84.
31. Apter D, Vihko R. Serum pregnenolone, progesterone, 17-hydroxyprogesterone, testosterone and 5 alpha-dihydrotestosterone during female puberty. *J Clin Endocrinol Metab.* 1977; 45(5):1039–48. [PubMed: 925129]
32. Apter D, Butzow TL, Laughlin GA, Yen SS. Gonadotropin-releasing hormone pulse generator activity during pubertal transition in girls: pulsatile and diurnal patterns of circulating gonadotropins. *J Clin Endocrinol Metab.* 1993; 76(4):940–9. [PubMed: 8473410]
33. Hardy TS, Norman RJ. Diagnosis of adolescent polycystic ovary syndrome. *Steroids.* 2013; 78(8): 751–4. [PubMed: 23624032]
34. van Hooff MH, Voorhorst FJ, Kaptein MB, Hirasig RA, Koppelaar C, Schoemaker J. Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. *Hum Reprod.* 2004; 19(2):383–92. [PubMed: 14747186]
35. Teede HJ, Misso ML, Deeks AA, Moran LJ, Stuckey BG, Wong JL, et al. Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline. *Med J Aust.* 2011; 195(6):S65–112. [PubMed: 21929505]

36. Hickey M, Doherty DA, Atkinson H, Sloboda DM, Franks S, Norman RJ, et al. Clinical, ultrasound and biochemical features of polycystic ovary syndrome in adolescents: implications for diagnosis. *Hum Reprod.* 2011; 26(6):1469–77. [PubMed: 21478180]
37. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. *J Clin Endocrinol Metab.* 1961; 21:1440–7. [PubMed: 13892577]
38. Lucky AW, Biro FM, Daniels SR, Cedars MI, Khoury PR, Morrison JA. The prevalence of upper lip hair in black and white girls during puberty: a new standard. *J Pediatr.* 2001; 138(1):134–6. [PubMed: 11148529]
39. Jeffrey Chang R, Coffler MS. Polycystic ovary syndrome: early detection in the adolescent. *Clin Obstet Gynecol.* 2007; 50(1):178–87. [PubMed: 17304035]
40. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. *J Clin Endocrinol Metab.* 2007; 92(2):405–13. [PubMed: 17090633]
41. Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. *Am J Obstet Gynecol.* 2010; 203(3):201, e1–5. [PubMed: 20435290]
42. Codner E, Villarroel C, Eyzaguirre FC, Lopez P, Merino PM, Perez-Bravo F, et al. Polycystic ovarian morphology in postmenarchal adolescents. *Fertil Steril.* 2011; 95(2):702–6. e1–2. [PubMed: 20650451]
43. Alsamarai S, Adams JM, Murphy MK, Post MD, Hayden DL, Hall JE, et al. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. *J Clin Endocrinol Metab.* 2009; 94(12):4961–70. [PubMed: 19846740]
44. Mortensen M, Rosenfield RL, Littlejohn E. Functional significance of polycystic-size ovaries in healthy adolescents. *J Clin Endocrinol Metab.* 2006; 91(10):3786–90. [PubMed: 16895960]
45. Khan U. Polycystic ovary syndrome in adolescents. *J Pediatr Adolesc Gynecol.* 2007; 20(2):101–4. [PubMed: 17418395]
46. Villa P, Rossodivita A, Sagnella F, Moruzzi MC, Mariano N, Lassandro AP, et al. Ovarian volume and gluco-insulinaemic markers in the diagnosis of PCOS during adolescence. *Clin Endocrinol (Oxf).* 2013; 78(2):285–90. [PubMed: 22724514]
47. Chen Y, Yang D, Li L, Chen X. The role of ovarian volume as a diagnostic criterion for Chinese adolescents with polycystic ovary syndrome. *J Pediatr Adolesc Gynecol.* 2008; 21(6):347–50. [PubMed: 19064229]
48. Flannery CA, Rackow B, Cong X, Duran E, Selen DJ, Burgert TS. Polycystic ovary syndrome in adolescence: impaired glucose tolerance occurs across the spectrum of BMI. *Pediatr Diabetes.* 2013; 14(1):42–9. [PubMed: 22925367]
49. Angioni S, Portoghese E, Milano F, Melis GB, Fulghesu AM. Diagnosis of metabolic disorders in women with polycystic ovary syndrome. *Obstet Gynecol Surv.* 2008; 63(12):796–802. [PubMed: 19017415]
50. Day C. Metabolic syndrome, or What you will: definitions and epidemiology. *Diab Vasc Dis Res.* 2007; 4(1):32–8. [PubMed: 17469041]
51. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation.* 2005; 112(17):2735–52. [PubMed: 16157765]
52. Zimmet P, Alberti G, Kaufman F, Tajima N, Silink M, Arslanian S, et al. The metabolic syndrome in children and adolescents. *Lancet.* 2007; 369(9579):2059–61. [PubMed: 17586288]
53. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA.* 2001; 285(19):2486–97. [PubMed: 11368702]
54. Huang PL. A comprehensive definition for metabolic syndrome. *Dis Model Mech.* 2009; 2(5–6): 231–7. [PubMed: 19407331]
55. Robinson S, Kiddy D, Gelding SV, Willis D, Niththyananthan R, Bush A, et al. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. *Clin Endocrinol (Oxf).* 1993; 39(3):351–5. [PubMed: 8222298]

56. Welt CK, Gudmundsson JA, Arason G, Adams J, Palsdottir H, Gudlaugsdottir G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. *J Clin Endocrinol Metab.* 2006; 91(12): 4842–8. [PubMed: 17003085]
57. Zhao Y, Qiao J. Ethnic differences in the phenotypic expression of polycystic ovary syndrome. *Steroids.* 2013; 78(8):755–60. [PubMed: 23624030]
58. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2006; 91(1):48–53. [PubMed: 16249284]
59. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2006; 91(4):1357–63. [PubMed: 16434451]
60. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. *J Clin Endocrinol Metab.* 1998; 83(6):2001–5. [PubMed: 9626131]
61. Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. *Clin Endocrinol (Oxf).* 2006; 65(2):137–45. [PubMed: 16886951]
62. Ibanez L, Jimenez R, de Zegher F. Early puberty-menarche after precocious pubarche: relation to prenatal growth. *Pediatrics.* 2006; 117(1):117–21. [PubMed: 16396868]
63. Stark O, Peckham CS, Moynihan C. Weight and age at menarche. *Arch Dis Child.* 1989; 64(3): 383–7. [PubMed: 2705803]
64. Carroll J, Saxena R, Welt CK. Environmental and genetic factors influence age at menarche in women with polycystic ovary syndrome. *J Pediatr Endocrinol Metab.* 2012; 25(5–6):459–66. [PubMed: 22876539]

Figure 1.
Prevalence of metabolic syndrome by group (% affected with SE bars, $p=0.27$)

Table 1

Clinical, metabolic and hormonal values by group expressed as mean (SD) except for MeS, expressed as number (%)

	PCOS _N	IM	ET	OC	p-value
N	24	25	6	43	
<i>Clinical Characteristics</i>					
Age range (yrs)	13–19.6	14–19.3	14.7–17.8	14.2–18.9	
Mean age (yrs)	16.8 (1.4)	16.0 (1.3)	16.0 (1.2)	16.5 (1.2)	0.18
BMI (kg/m ²)	47.5 (8.3)	49.8 (9.2)	46.6 (7)	44.4 (4.6)	0.03^a
Wt (kg)	125.5 (22)	134.0 (22)	123.8 (19)	124.0 (17.8)	0.23
Age Menarche (yrs)	10.8 (1.6)	11.2 (1.6)	11.3 (0.8)	11.8 (1.1)	0.056
Menarchal age (yrs)	5.9 (1.9)	4.8 (1.8)	4.7 (1.8)	4.7 (1.5)	0.03^b
MeS (%)	25	28	67	35	0.27
<i>HDL (mg/dL)</i>	44.7 (8)	42.5 (6)	45.3 (9)	43.2 (7)	0.68
<i>TG (mg/dL)</i>	101.1 (39)	93.4 (38)	87 (23)	98.9 (49)	0.85
<i>systolic BP%ile</i>	62.3 (28)	61.7 (32)	76.2 (23)	65.4 (28)	0.7
<i>diastolic BP%ile</i>	73.5 (25)	78.2 (19)	74.3 (20)	70.0 (19)	0.46
<i>WC (cm)</i>	131.5 (15)	137.8 (14)	128.2 (13)	130.4 (13)	0.16
<i>Fasting glucose(mg/dL)</i>	88 (27)	84.3 (6)	85.7 (6)	86.9 (10)	0.85
Other Metabolic and Hormonal Values					
HOMA-IR	3.6 (2.5)	2.9 (2)	3.1 (1)	2.8 (3)	0.7
HgbA1c (%)	5.7 (1)	5.6 (0.4)	5.8 (0.6)	5.5 (0.4)	0.42
AUC-G ₁₂₀ (mg/dL/minute)	130.4 (46)	120.9 (16)	125 (23)	109.4 (15)	0.018^b
AUC-I ₁₂₀ (μU/mL/minute)	57.1 (52)	65.7 (49)	58.2 (16)	39.9 (25)	0.07
Fasting Insulin (μU/mL)	16.1 (12)	13.7 (8)	14.9 (7)	13 (14)	0.81
Cholesterol (mg/dL)	169.3 (24)	160.2 (28)	166.8 (36)	160 (31)	0.57
LDL (mg/dL)	104.5 (22)	98.8 (24)	104 (39)	96.8 (26)	0.66
AST (U/L)	18.8 (5)	19.7 (7)	16.7 (3)	16.5 (4)	0.07
ALT (U/L)	21.3 (14)	20.8 (9)	15.5 (5)	16.7 (8)	0.16
LH (mIU/mL)	8.2 (6)	6.1 (3)	8.7 (3)	9.9 (15)	0.63

	PCOS _N	IM	ET	OC	p-value
N	24	25	6	43	
FSH (mIU/mL)	5.4 (2)	5.3 (2)	5.6 (2)	5.4 (3)	0.99
Estradiol (ng/dL)	18.5 (20)	14.1 (15)	47.2 (36)	28.9 (48)	0.19
Testosterone (ng/dL)	60.9 (22)	32.2 (10)	67 (16)	31.9 (12)	<0.0001 ^{bcd}
Free Testosterone (pg/mL)	11.5 (7)	5.4 (2)	9.3 (5)	5.2 (2)	<0.0001 ^{bc}
SHBG	30.3 (27)	27.0 (14)	42.2 (18)	27.0 (12)	0.24

Analysis for group comparisons done with ANOVA with the exception of MeS which used Fishers exact test

^aIM to OC

^bPCOS_N to OC

^cPCOS_N to IM

^dET to IM

^eET to OC

Table 2

Logistic Regression Models for MeS prediction

	Odds Ratio	CI	p-value
<i>Model #1 for MeS</i>			
Irregular Menses	0.4	0.16–1.04	0.059
BMI	0.48	0.26–0.92	0.027
<i>Model #2 for MeS</i>			
Testosterone	1.07	0.38–2.99	0.894
BMI	0.6	0.33–1.08	0.087
<i>Model #3 for MeS</i>			
PCOS	0.59	0.19–1.63	0.287
BMI	0.57	0.31–1.04	0.068